Chugai Pharmaceutical Co., Ltd.

Symbol: CHGCF

PNK

32.43

USD

Market price today

  • 25.4338

    P/E Ratio

  • -0.1023

    PEG Ratio

  • 53.36B

    MRK Cap

  • 0.00%

    DIV Yield

Chugai Pharmaceutical Co., Ltd. (CHGCF) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.68%

Operating Profit Margin

0.42%

Net Profit Margin

0.32%

Return on Assets

0.17%

Return on Equity

0.21%

Return on Capital Employed

0.26%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Dr. Osamu Okuda
Full-time employees:7604
City:Chuo
Address:2-1-1 Nihonbashi-Muromachi
IPO:2012-08-03
CIK:

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

General Outlook

When we look at how much money they make before expenses, they keep 0.677% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.420%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.315%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.172% return, is a testament to Chugai Pharmaceutical Co., Ltd.'s adeptness in optimizing resource deployment. Chugai Pharmaceutical Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.207%. Furthermore, the proficiency of Chugai Pharmaceutical Co., Ltd. in capital utilization is underscored by a remarkable 0.262% return on capital employed.

Stock Prices

Chugai Pharmaceutical Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $37, while its low point bottomed out at $37. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Chugai Pharmaceutical Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing CHGCF liquidity ratios reveals its financial health of the firm. The current ratio of 553.12% gauges short-term asset coverage for liabilities. The quick ratio (420.74%) assesses immediate liquidity, while the cash ratio (193.68%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio553.12%
Quick Ratio420.74%
Cash Ratio193.68%

Profitability Ratios

CHGCF profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 42.86% underscores its earnings before tax deductions. The effective tax rate stands at 26.50%, revealing its tax efficiency. The net income per EBT, 73.50%, and the EBT per EBIT, 102.04%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 42.00%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin42.86%
Effective Tax Rate26.50%
Net Income per EBT73.50%
EBT per EBIT102.04%
EBIT per Revenue42.00%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 5.53, it details the span from stock purchase to revenue. The 4 days it takes to settle debts showcases its creditor relations. Meanwhile, a 2 cash conversion cycle and 430.05% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding421
Days of Inventory Outstanding302
Operating Cycle386.40
Days of Payables Outstanding97
Cash Conversion Cycle290
Receivables Turnover4.30
Payables Turnover3.78
Inventory Turnover1.21
Fixed Asset Turnover2.43
Asset Turnover0.55

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 233.57, and free cash flow per share, 197.34, depict cash generation on a per-share basis. The cash per share value, 464.69, showcases liquidity position. A payout ratio of 0.40 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.37, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share233.57
Free Cash Flow per Share197.34
Cash per Share464.69
Payout Ratio0.40
Operating Cash Flow Sales Ratio0.37
Free Cash Flow to Operating Cash Flow Ratio0.84
Capital Expenditure Coverage Ratio6.45
Dividend Paid and Capex Coverage Ratio2.01
Dividend Payout Ratio0.02

Debt and Leverage Ratios

An interest coverage of 18132.88 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Interest Coverage18132.88
Company Equity Multiplier1.16

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 675.52, provides a glimpse into top-line earnings distributed across each share. Net income per share, 197.83, reflects the portion of profit attributed to each share. The book value per share, 988.07, represents the net asset value distributed per share, while the tangible book value per share, 976.00, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share675.52
Net Income Per Share197.83
Book Value Per Share988.07
Tangible Book Value Per Share976.00
Shareholders Equity Per Share988.07
Interest Debt Per Share8.19
Capex Per Share-45.14

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -11.79%, indicates top-line expansion, while the gross profit growth, -11.57%, reveals profitability trends. EBIT growth, -22.06%, and operating income growth, -22.06%, offer insights into operational profitability progression. The net income growth, -13.08%, showcases bottom-line expansion, and the EPS growth, -13.10%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-11.79%
Gross Profit Growth-11.57%
EBIT Growth-22.06%
Operating Income Growth-22.06%
Net Income Growth-13.08%
EPS Growth-13.10%
EPS Diluted Growth-13.08%
Weighted Average Shares Growth0.02%
Weighted Average Shares Diluted Growth0.01%
Dividends per Share Growth-4.82%
Operating Cash Flow Growth68.50%
Free Cash Flow Growth94.98%
10-Year Revenue Growth per Share160.47%
5-Year Revenue Growth per Share91.33%
3-Year Revenue Growth per Share41.07%
10-Year Operating CF Growth per Share663.10%
5-Year Operating CF Growth per Share244.79%
3-Year Operating CF Growth per Share100.40%
10-Year Net Income Growth per Share534.97%
5-Year Net Income Growth per Share251.25%
3-Year Net Income Growth per Share51.41%
10-Year Shareholders Equity Growth per Share182.33%
5-Year Shareholders Equity Growth per Share114.66%
3-Year Shareholders Equity Growth per Share65.70%
10-Year Dividend per Share Growth per Share471.23%
3-Year Dividend per Share Growth per Share43.76%
Receivables Growth-37.71%
Inventory Growth-6.41%
Asset Growth3.36%
Book Value per Share Growth14.10%
Debt Growth-4.64%
R&D Expense Growth10.12%
SGA Expenses Growth11.73%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 8,134,913,502,214.784, captures the company's total value, considering both debt and equity. Income quality, 1.26, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 1.03%, indicates the value of non-physical assets, and capex to operating cash flow, -18.05%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value8,134,913,502,214.784
Income Quality1.26
Research and Development to Revenue14.83%
Intangibles to Total Assets1.03%
Capex to Operating Cash Flow-18.05%
Capex to Revenue-6.68%
Capex to Depreciation-233.96%
Graham Number2097.16
Return on Tangible Assets17.02%
Graham Net Net491.74
Working Capital1,078,209,000,000
Tangible Asset Value1,605,721,000,000
Net Current Asset Value1,059,460,000,000
Average Receivables417,315,500,000
Average Payables132,034,500,000
Average Inventory282,843,000,000
Days Sales Outstanding105
Days Payables Outstanding47
Days of Inventory On Hand239
ROIC18.60%
ROE0.20%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 5.06, and the price to book ratio, 5.06, reflect the market's valuation relative to the company's book value. The price to sales ratio, 8.01, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 25.57, and price to operating cash flows, 21.60, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio5.06
Price to Book Ratio5.06
Price to Sales Ratio8.01
Price Cash Flow Ratio21.60
Price Earnings to Growth Ratio-0.10
Enterprise Value Multiple19.93
Price Fair Value5.06
Price to Operating Cash Flow Ratio21.60
Price to Free Cash Flows Ratio25.57
Price to Tangible Book Ratio5.28
Enterprise Value to Sales7.32
Enterprise Value Over EBITDA18.18
EV to Operating Cash Flow19.78
Earnings Yield3.79%
Free Cash Flow Yield3.93%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Chugai Pharmaceutical Co., Ltd. (CHGCF) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 25.434 in 2024.

What is the ticker symbol of Chugai Pharmaceutical Co., Ltd. stock?

The ticker symbol of Chugai Pharmaceutical Co., Ltd. stock is CHGCF.

What is company IPO date?

IPO date of Chugai Pharmaceutical Co., Ltd. is 2012-08-03.

What is company current share price?

Current share price is 32.430 USD.

What is stock market cap today?

The market cap of stock today is 53359809022.000.

What is PEG ratio in 2024?

The current -0.102 is -0.102 in 2024.

What is the number of employees in 2024?

In 2024 the company has 7604.